Renaissance Technologies (RenTech)'s NVCR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 1.39 M shares of NovoCure Limited (NVCR) worth $17.94 M, representing 0.03% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in NVCR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2019, adding 785,800 shares. Largest reduction occurred in Q3 2020, reducing 1.02 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s NovoCure Limited (NVCR) Holding Value Over Time
Track share changes against reported price movement
Quarterly NovoCure Limited (NVCR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +314,900 | Add 29.35% | 1.39 M | $12.93 |
| Q3 2025 | -227,200 | Reduce 17.48% | 1.07 M | $12.92 |
| Q2 2025 | +531,400 | Add 69.13% | 1.3 M | $17.80 |
| Q1 2025 | +34,300 | Add 4.67% | 768,654 | $17.82 |
| Q4 2024 | -9,800 | Reduce 1.32% | 734,354 | $29.80 |
| Q3 2024 | -16,021 | Reduce 2.11% | 744,154 | $15.63 |
| Q2 2024 | +480,600 | Add 171.90% | 760,175 | $17.13 |
| Q1 2024 | +178,200 | Add 175.78% | 279,575 | $15.63 |
| Q4 2023 | +101,375 | New Buy | 101,375 | $14.93 |
| Q3 2022 | -18,386 | Sold Out | 0 | $0.00 |
| Q2 2022 | -29,589 | Reduce 61.68% | 18,386 | $69.51 |
| Q1 2022 | -131,116 | Reduce 73.21% | 47,975 | $82.86 |
| Q4 2021 | -34,884 | Reduce 16.30% | 179,091 | $75.08 |
| Q3 2021 | -12,800 | Reduce 5.64% | 213,975 | $116.17 |
| Q2 2021 | -181,800 | Reduce 44.50% | 226,775 | $221.82 |
| Q1 2021 | +110,605 | Add 37.12% | 408,575 | $132.18 |
| Q4 2020 | -679,700 | Reduce 69.52% | 297,970 | $173.04 |
| Q3 2020 | -1.02 M | Reduce 51.13% | 977,670 | $111.31 |
| Q2 2020 | -244,900 | Reduce 10.91% | 2 M | $59.30 |
| Q1 2020 | +3,475 | Add 0.15% | 2.25 M | $67.34 |
| Q4 2019 | -133,775 | Reduce 5.63% | 2.24 M | $84.27 |
| Q3 2019 | +320,300 | Add 15.58% | 2.38 M | $74.78 |
| Q2 2019 | +199,200 | Add 10.73% | 2.06 M | $63.23 |
| Q1 2019 | +785,800 | Add 73.41% | 1.86 M | $48.17 |
| Q4 2018 | +231,275 | Add 27.56% | 1.07 M | $33.48 |
| Q3 2018 | +156,592 | Add 22.94% | 839,195 | $52.40 |
| Q2 2018 | +501,203 | Add 276.30% | 682,603 | $31.30 |
| Q1 2018 | -74,875 | Reduce 29.22% | 181,400 | $21.80 |
| Q4 2017 | +256,275 | New Buy | 256,275 | $20.20 |
Renaissance Technologies (RenTech)'s NovoCure Limited Investment FAQs
Renaissance Technologies (RenTech) first purchased NovoCure Limited (NVCR) in Q4 2017, acquiring 256,275 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held NovoCure Limited (NVCR) for 29 quarters since Q4 2017.
Renaissance Technologies (RenTech)'s largest addition to NovoCure Limited (NVCR) was in Q1 2019, adding 1,856,270 shares worth $89.42 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 1,387,754 shares of NovoCure Limited (NVCR), valued at approximately $17.94 M.
As of the Q4 2025 filing, NovoCure Limited (NVCR) represents approximately 0.03% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in NovoCure Limited (NVCR) was 2,375,770 shares, as reported at the end of Q3 2019.